Baidu
map

FDA接受了全球早衰症治疗药物Zokinvy的新药申请

2020-06-03 MedSci原创 MedSci原创

Zokinvy是法呢基转移酶的口服抑制剂,通过阻断早老蛋白的法尼基化来发挥作用。

Eiger BioPharmaceuticals宣布美国食品美国药品监督管理局(FDA)接受了其Zokinvy(lonafarnib)的新药申请(NDA),以加快审批用于治疗早衰症。

早衰症,又称哈钦森-吉尔福德早衰症(HGPS),是一种罕见的先天性遗传性疾病。早衰是由LMNA的基因突变引起法呢基化蛋白Progerin的异常产生所造成。

Zokinvy是法呢基转移酶的口服抑制剂,通过阻断早老蛋白的法尼基化来发挥作用。在波士顿儿童医院的1/2期和2期研究中已向90多名早衰症儿童使用。研究数据表明,用Zokinvy单药治疗的早衰症患者具有生存优势,死亡率降低了88%。最常见的不良反应是胃肠道疾病。

Zokinvy已被FDA和EMA授予早衰孤儿药称号,并被FDA授予突破性疗法称号和罕见儿科疾病称号。

原始出处:

https://www.firstwordpharma.com/node/1725910?tsid=4

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1744212, encodeId=f23c1e4421249, content=<a href='/topic/show?id=657a58646ca' target=_blank style='color:#2F92EE;'>#新药申请#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58646, encryptionId=657a58646ca, topicName=新药申请)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab3c35313981, createdName=wangbingxhy, createdTime=Mon Oct 26 01:08:13 CST 2020, time=2020-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1921796, encodeId=fd951921e96d3, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64698, encryptionId=4f0a6469837, topicName=治疗药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Mon Dec 28 11:08:13 CST 2020, time=2020-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530837, encodeId=b825153083ecc, content=<a href='/topic/show?id=f9cd5950630' target=_blank style='color:#2F92EE;'>#早衰症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59506, encryptionId=f9cd5950630, topicName=早衰症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea8212147736, createdName=zhangfenasdf, createdTime=Fri May 22 06:08:13 CST 2020, time=2020-05-22, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1744212, encodeId=f23c1e4421249, content=<a href='/topic/show?id=657a58646ca' target=_blank style='color:#2F92EE;'>#新药申请#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58646, encryptionId=657a58646ca, topicName=新药申请)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab3c35313981, createdName=wangbingxhy, createdTime=Mon Oct 26 01:08:13 CST 2020, time=2020-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1921796, encodeId=fd951921e96d3, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64698, encryptionId=4f0a6469837, topicName=治疗药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Mon Dec 28 11:08:13 CST 2020, time=2020-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530837, encodeId=b825153083ecc, content=<a href='/topic/show?id=f9cd5950630' target=_blank style='color:#2F92EE;'>#早衰症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59506, encryptionId=f9cd5950630, topicName=早衰症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea8212147736, createdName=zhangfenasdf, createdTime=Fri May 22 06:08:13 CST 2020, time=2020-05-22, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1744212, encodeId=f23c1e4421249, content=<a href='/topic/show?id=657a58646ca' target=_blank style='color:#2F92EE;'>#新药申请#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58646, encryptionId=657a58646ca, topicName=新药申请)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab3c35313981, createdName=wangbingxhy, createdTime=Mon Oct 26 01:08:13 CST 2020, time=2020-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1921796, encodeId=fd951921e96d3, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64698, encryptionId=4f0a6469837, topicName=治疗药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Mon Dec 28 11:08:13 CST 2020, time=2020-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530837, encodeId=b825153083ecc, content=<a href='/topic/show?id=f9cd5950630' target=_blank style='color:#2F92EE;'>#早衰症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59506, encryptionId=f9cd5950630, topicName=早衰症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea8212147736, createdName=zhangfenasdf, createdTime=Fri May 22 06:08:13 CST 2020, time=2020-05-22, status=1, ipAttribution=)]

相关资讯

JAMA子刊:2/3早衰症儿童心功能受损,年龄越大越明显

儿童早衰症(HGPS)是一种极其罕见的、致命性的、散发性的遗传综合征,每4百万到8百万新生儿中就有1人患有此综合征。他们的临床症状很独特,表现为身材矮小,体重低,头发脱光,脂肪营养不良,硬皮病样皮肤改变。患病儿童平均存活年龄为13岁,最后往往死于心脏疾病。值得一提的是,HGPS类似于衰老,但不完全等同于衰老。

AGING CELL:研究人员发现早衰治疗新靶标

应激反应的缺陷是细胞衰老和机体衰老的主要决定因素。Hutchinson-Gilford早衰症是与骨吸收,心血管疾病和早衰相关的严重的LMNA相关综合征。

北医三院利用博雅干细胞新技术拯救早衰症女孩

日前,北京大学第三医院联合博雅干细胞运用干细胞治疗手段为一位14岁早衰症女孩,实施治疗并达到预期治疗效果。成为国际首例胎盘干细胞治疗早衰症的病例,也是干细胞技术在临床应用领域的全新突破。 事件的主人公桐桐,是一个14岁的女孩,却拥有一副80岁老人的衰老身体:眼窝凹陷,骨瘦如柴,并且完全失去了听力。这是一种世界罕见的疾病——科凯恩氏综合征(早衰症),发病率为百万分之一。患者身体衰老

Baidu
map
Baidu
map
Baidu
map